For the quarter ending 2026-03-31, MAIA had $25,755,079 increase in cash & cash equivalents over the period.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Australia research and development incentives receivable | - | -80,410 | - | 0 |
| Loss on fair value of warrants over proceeds | - | 0 | - | 0 |
| Net loss | -6,369,652 | -3,628,762 | -8,903,188 | -9,864,222 |
| Stock-based compensation | 650,024 | 810,796 | 646,900 | 1,173,956 |
| Consulting and research expense for restricted shares issued | - | - | 187,313 | 62,321 |
| Restricted shares issued for consulting and research expense | - | 618,813 | - | - |
| Restricted stock issued for consulting expense | 43,651 | - | - | - |
| Change in fair value of warrant liability | -254,955 | -253,512 | -379,311 | -565,387 |
| Prepaid expenses and other current assets | -137,114 | 238,952 | -11,443 | 352,257 |
| Accounts payable | 940,877 | -1,138,512 | 1,452,201 | 206,031 |
| Accrued expenses | -458,387 | -3,021,118 | 3,498,126 | 1,001,947 |
| Net cash used in operating activities | -5,311,328 | -7,020,471 | -3,486,516 | -8,337,611 |
| Proceeds from exercise of warrants | - | 0 | 572,654 | 328,924 |
| Proceeds from private placement-Private Placement Offering One Twenty Twenty Five | - | 0 | 0 | 2,715,000 |
| Proceeds from private placement-Private Placement Offering Two Twenty Twenty Five | - | 0 | 0 | 1,428,949 |
| Proceeds from private placement-Private Placement Offering Three Twenty Twenty Five | - | 0 | 0 | 1,079,998 |
| Proceeds from private placement-Private Placement Offering One Twenty Twenty Four | - | 0 | - | 0 |
| Proceeds from private placement-Private Placement Offering Two Twenty Twenty Four | - | 0 | - | 0 |
| Proceeds from private placement-Private Placement Offering Four Twenty Twenty Five | - | 0 | 0 | 694,999 |
| Proceeds from private placement-Private Placement Offering Three Twenty Twenty Four | - | 0 | - | 0 |
| Proceeds from private placement-Private Placement Offering Five Twenty Twenty Five | - | 2,253,900 | - | - |
| Proceeds from private placement-Private Placement Offering Four Twenty Twenty Four | - | 0 | - | - |
| Proceeds from private placement-Private Placement Offering Six Twenty Twenty Five | - | 736,600 | - | - |
| Proceeds from private placement-Private Placement Offering Five Twenty Twenty Four | - | 0 | - | - |
| Proceeds from private placement-Private Placement Offering Seven Twenty Twenty Five | - | 1,509,796 | - | - |
| Proceeds from exercise of stock options | 38,549 | 0 | 0 | 844 |
| Proceeds from confidentially marketed public offering | 33,008,813 | 420,780 | 3,779,251 | 3,001,985 |
| Payment of offering transactions costs | 1,995,041 | 118,704 | 117,136 | 381,293 |
| Net cash provided by financing activities | 31,052,321 | 4,802,372 | 4,234,769 | 8,869,406 |
| Net effect of foreign currency exchange on cash | 14,086 | -15,606 | -1,039 | 11,429 |
| Net increase in cash | 25,755,079 | -2,233,705 | 747,214 | 543,224 |
| Cash at beginning of period | 8,658,031 | 10,891,736 | 9,601,298 | - |
| Cash at end of period | 34,413,110 | 8,658,031 | 10,891,736 | - |
MAIA Biotechnology, Inc. (MAIA)
MAIA Biotechnology, Inc. (MAIA)